<DOC>
	<DOCNO>NCT00005987</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . Colony-stimulating factor filgrastim sargramostim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . Interferon alfa may interfere growth cancer cell . It yet know treatment regimen effective multiple myeloma . PURPOSE : Randomized phase II trial compare effectiveness filgrastim sargramostim plus chemotherapy , peripheral stem cell transplantation , interferon alfa treat patient multiple myeloma .</brief_summary>
	<brief_title>Filgrastim Compared With Sargramostim Plus Chemotherapy , Peripheral Stem Cell Transplantation , Interferon Alfa Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Compare disease control extend survival patient multiple myeloma treat either filgrastim ( G-CSF ) sargramostim ( GM-CSF ) plus high-dose chemotherapy follow autologous peripheral blood stem cell ( PBSC ) transplantation follow interferon alfa . - Determine whether prim treatment induce sufficient mobilization circulate PBSC allow collection leukapheresis subsequent use autologous transplantation patient . - Determine whether treatment induce complete response conjunction rapid hematopoietic recovery modest transplant-associated morbidity mortality patient population . - Determine whether interferon alfa , give maintenance immunostimulatory therapy patient achieve significant cytoreduction post transplantation , prevent delay malignant relapse patient . OUTLINE : This randomize study . Patients randomize one two treatment arm . - Arm I : In prim phase , patient receive cyclophosphamide IV 2 hour day 1 , mitoxantrone IV 1 hour daily day 1-2 , dexamethasone IV every 12 hour begin day 1 total 4 dos . Patients also receive sargramostim ( GM-CSF ) IV 2 hour subcutaneously ( SC ) daily begin 48 hour last dose mitoxantrone continue completion leukapheresis . Peripheral blood stem cell ( PBSC ) collect daily day 11-13 neutrophil recovery . - Arm II : In prim phase , patient receive treatment arm I except patient receive filgrastim ( G-CSF ) IV 15 minute SC place GM-CSF . In transplant phase , patient receive prior radiotherapy receive cyclophosphamide IV 2 hour daily day -6 -5 total body irradiation twice daily day -3 -1 . Autologous PBSC reinfused day 0 . Patients also receive GM-CSF IV 2 hour daily G-CSF IV 15 minute daily begin day 0 continue day 28 blood count recover . Patients receive prior radiotherapy receive cyclophosphamide IV 2 hour daily day -6 -3 , carmustine IV 1 hour day -6 , etoposide IV 4 hour every 12 hour total 6 dos day -6 -4 . Autologous PBSC reinfused day 0 . Patients also receive GM-CSF IV 2 hour daily G-CSF IV 15 minute daily begin day 0 continue day 28 blood count recover . All patient receive interferon alfa SC 3 time weekly start day 28 continue relapse disease progression . Patients may also undergo radiotherapy 5 day week 2 week residual bony lesion measure great 2 cm . Patients follow day 28 100 , 6 , 9 , 12 , 18 , 24 , 30 , 36 month . PROJECTED ACCRUAL : A total 25-35 patient accrue study within 2-3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm multiple myeloma Complete partial remission initial therapy OR Complete partial response therapy disease progression follow initial therapy No plasma cell leukemia ( great 10 % circulate plasma cell ) No advanced myeloma refractory unresponsive least 2 salvage chemotherapy regimens PATIENT CHARACTERISTICS : Age : 70 Performance status : Age 6570 year : Karnofsky 80100 % Under 65 year : Not specify Life expectancy : Not specify Hematopoietic : Hemoglobin least 8 g/dL ( untransfused ) WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 ( untransfused ) Hepatic : Bilirubin le 2.0 mg/dL ALT le 3 time upper limit normal Renal : Age 6570 year : Creatinine clearance great 60 mL/min ( creatinine least 1.5 mg/dL ) Under 65 year : Creatinine le 2 mg/dL Cardiovascular : Age 6570 year : LVEF least 45 % Under 65 year : No active ischemia LVEF great 45 % MUGA Pulmonary : Age 6570 year : If history smoking respiratory symptom , spirometry DLCO must great 50 % predict Under 65 year : FEV_1 FVC great 60 % predict DLCO great 50 % predict Other : No active uncontrolled infection PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>